News from syndax pharmaceuticals inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Aug 26, 2015, 08:00 ET

Syndax Enters Clinical Trial Collaboration in Cancer Immunotherapy Combining Entinostat and Atezolizumab

 Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing entinostat as a combination therapy in multiple...

Aug 24, 2015, 08:00 ET

Syndax Raises $80 Million In Series C Financing

 Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing entinostat as a combination therapy in multiple cancer...

Jun 15, 2015, 08:00 ET

Syndax Appoints Dr. Briggs W. Morrison as Chief Executive Officer and Michael A. Metzger as President and Chief Operating Officer

 Syndax Pharmaceuticals, Inc., a privately held oncology company, announced today that Briggs W. Morrison, M.D. is joining the Company as Chief...

Mar 12, 2015, 08:00 ET

Syndax to Participate in Two Upcoming Conferences

 Syndax Pharmaceuticals, Inc., today announced that Arlene Morris, president and chief executive officer, will be participating in two upcoming...

Feb 05, 2015, 12:00 ET

Syndax to Present at 2015 BIO CEO & Investor Conference

 Syndax Pharmaceuticals, Inc., today announced that chief executive officer, Arlene Morris, will be presenting a corporate overview at the 17th...

Jan 07, 2015, 19:00 ET

Kyowa Hakko Kirin and Syndax Announce an Exclusive License Agreement to Develop and Commercialize Entinostat in Japan and Korea

 Kyowa Hakko Kirin Co., Ltd., (Headquarters: Chiyoda-ku, Tokyo; president and CEO: Nobuo Hanai, "Kyowa Hakko Kirin") and Syndax...

Jul 30, 2014, 08:00 ET

Entinostat Improves Treatment Outcomes When Combined with Immune Checkpoint Blockade in Preclinical Tumor Models

Syndax Pharmaceuticals, Inc. today announced that newly published results demonstrate that in preclinical studies entinostat significantly improved...

May 27, 2014, 08:00 ET

Syndax Announces Presentation of Entinostat Data in Two Posters at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting

 Syndax Pharmaceuticals, Inc., today announced that clinical trial data on entinostat will be presented in two posters during the 50th Annual...

Mar 27, 2014, 18:43 ET

Syndax Files Registration Statement for Proposed Initial Public Offering

 Syndax Pharmaceuticals, Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange...

Feb 13, 2014, 08:00 ET

Syndax Announces NCI and FDA Reach Agreement on a Special Protocol Assessment (SPA) for the Phase 3 Trial of Entinostat in Patients with Advanced ER+ Breast Cancer

Syndax Pharmaceuticals, Inc., today announced that the Division of Cancer Treatment and Diagnosis (DCTD) of the National Cancer Institute (NCI) has...

Feb 03, 2014, 08:00 ET

Leading Breast Cancer Expert, George W. Sledge, Jr., M.D., Joins Syndax as an Independent Director

 Syndax Pharmaceuticals, Inc., today announced the appointment of distinguished breast cancer specialist, George W. Sledge, Jr., M.D., to its...

Jan 23, 2014, 08:00 ET

Syndax Announces Appointment of Richard P. Shea as Independent Director and Chair of the Audit Committee

 Syndax Pharmaceuticals, Inc. today announced the appointment of Richard P. Shea to its board of directors as an independent director and...

Nov 01, 2013, 08:00 ET

Syndax Promotes John S. Pallies to Chief Financial Officer and Dr. Peter Ordentlich to Chief Technology Officer

Syndax Pharmaceuticals, Inc. today announced the promotion of John S. Pallies to chief financial officer from vice president, finance and...

Oct 11, 2013, 08:00 ET

Syndax Names Steven M. Fruchtman, M.D., Chief Medical Officer

 Syndax Pharmaceuticals Inc. today announced the appointment of Steven M. Fruchtman, M.D., a hematologist/oncologist...

Sep 11, 2013, 08:00 ET

Syndax's Entinostat Receives Breakthrough Therapy Designation from FDA for Treatment of Advanced Breast Cancer

 Syndax Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated entinostat as a...

Sep 04, 2013, 08:00 ET

Syndax and Eddingpharm Enter into a License Agreement Giving Eddingpharm Rights to Commercialize Entinostat in China and Other Asian Countries

 Syndax Pharmaceuticals Inc., which is developing epigenetic therapies for treatment-resistant cancers and Eddingpharm, a leading specialty...

Aug 27, 2013, 08:00 ET

Syndax Pharmaceuticals Secures $26.6 Million Series B Financing for Advancement of Epigenetic Therapies for Treatment-Resistant Cancers

 Syndax Pharmaceuticals Inc., which is developing epigenetic therapies for treatment-resistant cancers, today announced it has secured a $26.6...

May 14, 2013, 08:30 ET

Syndax Pharmaceuticals Announces Publication of Clinical Study Demonstrating that Entinostat Targets Resistance Pathways in Breast Cancer

 Syndax Pharmaceuticals, Inc., a late-stage oncology company focused on developing novel combination epigenetic strategies to treat cancers...

May 29, 2012, 08:30 ET

Syndax Pharmaceuticals to Present Updated Overall Survival Data With Entinostat in Metastatic Breast Cancer at ASCO

 Syndax Pharmaceuticals, Inc., a late-stage oncology company, announced today that updated results from ENCORE 301, a randomized,...

May 16, 2012, 08:30 ET

Syndax Pharmaceuticals Appoints Luke Evnin, Ph.D. to Board of Directors

 Syndax Pharmaceuticals, Inc., an oncology company moving into phase 3 having completed randomized, placebo controlled phase 2 studies,...